Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's disease treated with mirikizumab achieved histologic response at Week 52 ...

Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring sales thanks to its dominance in the high-growth weight loss drug market.

Eli Lilly has become a household name thanks to breakthrough diabetes and obesity care medicines. The stock has trounced the broader market over the past year, and shares have become a bit pricey.

Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their medical records for safety reasons, a move that comes as it builds a case ...

Eli Lilly and Company will invest an additional $4.5 billion in Boone County to create a new center for advanced manufacturing and drug development.

Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic diseases. But the deal is a little different compared to many recent ...

Gift 5 articles to anyone you choose each month when you subscribe. Times are good at Eli Lilly. Wall Street’s insatiable appetite for weight-loss drug stocks looks set to turn the company into ...

Eli Lilly's long-term growth prospects have been secured by the improved supply in H2'24 and the incoming capacity additions from H1'25 onwards. This is on top of the introduction of its D2C ...

Oct 7 (Reuters) - A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s (LLY.N), opens new tab blockbuster weight loss and ...

Zoe Garces, left, of St. Joseph and Annabel Edwards of Staples fight for the ball at their girls soccer game in Trumbull on ...

Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its competitor. Eli Lilly (LLY) has partnered with the government of the ...